We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Gkb7.0
Ginkgo Biloba Research
Probably helps
278 peer-reviewed studies
What the evidence says
Likely helps
Ginkgo Biloba appears to help in 9 of 11 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2026 with a typical study size of 1,104 participants.
Based on 278 studies · 50 meta-analyses · 175 RCTs · 79,364 total participants
Confidence
High confidence
What the studies found
9helped2unclear· 267 more without graded effect data
By outcome
Cognitive functionModest cognitive benefit in dementia/cognitive decline; no measurable memory benefit in healthy adults · 12-24 weeks
Likely helps225 studies
Neuroprotection & brain agingImproves cerebral blood flow and antioxidant defence in CNS · 8-12 weeks
Focus & attentionNo measurable effect on attention or executive function in healthy adults · 4-6 weeks
Mostly mechanism / observational3 studies
Inflammation
Mostly mechanism / observational3 studies
Glucose & metabolic
Mostly mechanism / observational3 studies
By the numbers
Pulled from 47 studies with measurable effects
Likely real effects
100%
across studies
People studied
79k
typical study: 1104 people
Strongest designs
225
50 pooled, 175 randomised
Showed benefit
82%
9/11 studies
How long studies ran
1–4 weeks
1
1–3 months
1
3+ months
3
Populations Studied
Patients with tinnitus3
Patients with dementia3
Patients with mild dementia1
Children and adolescents with ADHD1
Steady research
71 studies in the last 5 years · Latest meta-analysis: 2026
199720112026
1Cognitive function in mild dementiaMeta-Analysisn=782 · large study2025
In plain English: The meta-analysis demonstrates that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment and quality of life.
Riepe M et al. · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2025)
The meta-analysis demonstrates that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment and quality of life.
In plain English: In this network meta-analysis of studies of patients with AD and a follow-up period of at least 1 year, EGb 120 mg demonstrated cognitive benefits, while placebo posed the least harm for AD.
Deng X et al. · Medicine (2024)
The network meta-analysis resulted indicated that placebo demonstrated greater effectiveness compared to Atorvastatin-calcium 80 mg (mean different [MD] = -6.93, confidence interval [CI] -11.57, -2.29) and Rivastigmine 12 mg (MD = -3.33, CI -6.56, -0.09).
In this network meta-analysis of studies of patients with AD and a follow-up period of at least 1 year, EGb 120 mg demonstrated cognitive benefits, while placebo posed the least harm for AD.
More RCTs are required to address the uncertainty surrounding the efficacy of medication.
3ADHD symptom improvement with antioxidantsMeta-Analysisn=3,650 · very large study2024
In plain English: The rankings of safety and efficacy of the 12 antioxidants vary.
Zhou P et al. · PloS one (2024)
The rankings of safety and efficacy of the 12 antioxidants vary.
Due to the low methodological quality of the included studies, the probability ranking cannot fully explain the clinical efficacy, and the results need to be interpreted with caution.
More high-quality studies are still needed to verify our findings.
5Health-related quality of life (Glasgow Health Status Inventory)Systematic Reviewn=1,915 · large study2022
In plain English: There is uncertainty about the benefits and harms of Ginkgo biloba for the treatment of tinnitus when compared to placebo.
Sereda M et al. · The Cochrane database of systematic reviews (2022)
No clear effect
← WorseNo effectBetter →
One study found that there may be little to no difference between the effects of Ginkgo biloba and placebo on health-related quality of life measured with the Glasgow Health Status Inventory at three months (MD -0.58 (scale 0 to 100), 95% CI -4.67 to 3.51; 1 study; 60 participants) (low-certainty).
Ginkgo biloba may not increase the frequency of other adverse effects (gastrointestinal upset, headache, allergic reaction) at three months compared to placebo (risk ratio 0.91, 95% CI 0.52 to 1.60; 4 studies; 1175 participants) (low-certainty).
There is uncertainty about the benefits and harms of Ginkgo biloba for the treatment of tinnitus when compared to placebo.
6Serum CRP reductionMeta-Analysisn=1,104 · large study2022
In plain English: Therefore, this medicinal herb might be a possible strategy for inflammation control.
Mousavi SN et al. · Phytotherapy research : PTR (2022)
Noticeable benefit
← WorseNo effectBetter →
Likely real
In the meta-analysis, the weighted mean differences (WMD) in change for serum CRP were -1.5 mg/L (95% CI: -2.16, -0.85, p < 0.001).
Moreover, WMD for serum IL-6 and TNF-α were in favor of the GBLE compared to the placebo [(-16.86 pg/mL, 95% CI: -19.38, -14.34, p < 0.001); and (-4.19 pg/mL, 95%CI: -5.14, -3.23, p < 0.001), respectively].
Subgroup analysis showed that GBLE has a beneficial effect on serum CRP at the baseline levels≥3 mg/L and doses<500 mg/day.
7Cognition, function, behavior, and global changeMeta-Analysisn=2,561 · very large study2015
In plain English: EGb761 at 240 mg/day is able to stabilize or slow decline in cognition, function, behavior, and global change at 22-26 weeks in cognitive impairment and dementia, especially for patients with neuropsychiatric symptoms.
Tan MS et al. · Journal of Alzheimer's disease : JAD (2015)
EGb761 at 240 mg/day is able to stabilize or slow decline in cognition, function, behavior, and global change at 22-26 weeks in cognitive impairment and dementia, especially for patients with neuropsychiatric symptoms.
9Repigmentation in vitiligoMeta-Analysisn=4,512 · very large study2015
In plain English: This review has found some evidence from individual studies to support existing therapies for vitiligo, but the usefulness of the findings is limited by the different designs and outcome measurements and lack of quality of life measures.
Whitton ME et al. · The Cochrane database of systematic reviews (2015)
All of the studies assessed repigmentation, however only five reported on all of our three primary outcomes which were quality of life, > 75% repigmentation and adverse effects.
This review has found some evidence from individual studies to support existing therapies for vitiligo, but the usefulness of the findings is limited by the different designs and outcome measurements and lack of quality of life measures.
There is a need for follow-up studies to assess permanence of repigmentation as well as high- quality randomised trials using standardised measures and which also address quality of life.
10Tardive dyskinesia symptom reliefMeta-Analysisn=1,278 · large study2018
In plain English: This review has found that the use of valbenazine or extract of Ginkgo biloba may be effective in relieving the symptoms of tardive dyskinesia.
Soares-Weiser K et al. · The Cochrane database of systematic reviews (2018)
Noticeable benefit
← WorseNo effectBetter →
Studies were primarily of short (three to six6 weeks) duration with small samples size (10 to 157 participants), and most (61%) were published more than 20 years ago.
Two studies found moderate-quality evidence of a benefit of the intervention compared with placebo: valbenazine (RR 0.63, 95% CI 0.46 to 0.86, 1 RCT, n = 92) and extract of Ginkgo biloba (RR 0.88, 95% CI 0.81 to 0.96, 1 RCT, n = 157), respectively.
This review has found that the use of valbenazine or extract of Ginkgo biloba may be effective in relieving the symptoms of tardive dyskinesia.